Congress Coverage: ESMO 2020 – Focus on Melanoma

Expert perspectives on the latest therapeutic developments, treatment approaches, and implications for clinical decision-making regarding melanoma adjuvant and neoadjuvant therapies, and BRAF-mutated metastatic melanoma.

September 22, 2020


Jeffrey S. Weber, MD, PhD

Deputy Director of the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, New York, NY, US

Faculty Members

Michael Atkins, MD
Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC, US

Alexander Eggermont, MD, PhD
Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands

James Larkin, MD
The Royal Marsden, London, UK

Reinhard Dummer, MD
University Hospital of Zurich, Zurich, Switzerland

Caroline Robert, MD, PhD
Institute Gustave-Roussy, Paris, France

Sample Report

Start discovering the insights

View Report


  • Clinical experts from across the world discussed global perspectives on current treatment strategies and emerging therapies in melanoma derived from ESMO 2020 data.
  • The goal of the expert panel was to critique and debate new evidence in melanoma and gain strategic insight into the most impactful abstracts from the ESMO meeting with respect to shaping current research directions and/or changing the scope of practical clinical care

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.